Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Opus Genetics, Inc. (IRD) is a Biotechnology company based in US with a market capitalization of $252.7M. Revenue grew 29.1% year-over-year and free cash flow was negative at -$35.3M. This page tracks IRD's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 18 employees · IPO Jan 19, 2015
Valuation
Valuation & price
$2.87as of Jul 24, 2026· -50.1% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
16.46
P/B ratio
Market cap ÷ book equity
No dividend
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$252.7M
Market cap
29.1%
Revenue growth (YoY)
100.0%
Gross margin
-$35.3M
Free cash flow (USD)
-$45.1M
Net debt
Net cash position
2229.1%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 21, 2026 (EPS $-0.19)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 16, 2026Filing
R&D Science Forum Announcement
- 8-K eventJun 16, 2026Filing
R&D Science Forum
- FinancingJun 5, 2026Filing
Securities Registration
- 8-K eventMay 12, 2026Filing
Earnings Release
- Quarterly reportMay 12, 2026Filing
10-Q Filed
- 8-K eventApr 24, 2026Filing
Debt Financing
- 8-K eventApr 22, 2026Filing
Annual Meeting Results
- FinancingApr 21, 2026Filing
Securities Registration
- 8-K eventApr 7, 2026Filing
Note Purchase Agreement
- 8-K eventApr 7, 2026Filing
Change in Control Agreement
Questions
Frequently asked questions
What is Opus Genetics, Inc.'s market cap?
Opus Genetics, Inc. (IRD) has a market capitalization of $252.7M.
What is IRD's P/E ratio?
A meaningful P/E ratio is not available for IRD — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is IRD's price-to-book (P/B) ratio?
IRD trades at 16.46 times book value per share.
Does Opus Genetics, Inc. pay a dividend?
No — IRD did not pay a dividend in its latest reported fiscal year.
When did Opus Genetics, Inc. last report earnings?
IRD last reported earnings on May 21, 2026; the next date is not yet scheduled.
Are insiders buying IRD stock?
SEC Form 4 filings show no open-market insider buys at Opus Genetics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.